boehringer ingelheim investor presentation 2022

Boehringer Ingelheim reaches more patients than ever in 2022 as innovative medicines drive growth

• Medicines reached a record 30 million people, driven by JARDIANCE® and OFEV®
• R&D investments of 5 billion EUR, or 21 percent of net sales
• Net sales rise 10.5 percent (currency adjusted), up strongly to 24.1 billion EUR

INGELHEIM, Germany--( BUSINESS WIRE )--Boehringer Ingelheim today reported a strong performance in 2022, a year in which 30 million patients benefited from its innovative medicines, while deepening investments in the search for new treatments. Research & development investments reached 5 billion EUR, or 21 percent of net sales. Net sales rose by a currency-adjusted 10.5 percent to 24.1 billion EUR.

“ 2022 has shown that our long-term commitment to medical research is the right strategy. For some patient conditions that were until recently deemed difficult to treat, we have now found medical entities that can be true breakthroughs,” said Hubertus von Baumbach, Chairman of the Board of Managing Directors. “ The acceleration of our broad pipeline demonstrates our commitment to transform the treatment of cardiovascular-renal diseases, inflammation, and respiratory diseases, as well as mental health, oncology and retinal diseases.”

Development of the pipeline progressed very well in 2022. Boehringer Ingelheim received one Breakthrough Designation, three Fast Track Designations, and two Orphan Drug Designations from the FDA. In the next seven years the company expects about 20 regulatory approvals in human pharma. Throughout the current year, Boehringer Ingelheim expects to present additional data from its pipeline.

In 2022 operating income at Group level rose by 1.4 percent to 4.8 billion EUR, while income after taxes amounted to 3.2 billion EUR.

“ The strong commercial performance provides a solid base to finance our late-stage pipeline, mid-term growth opportunities, as well as further investments in new technologies. It will enable us to address future unmet patient needs,” said Michael Schmelmer, Member of the Board of Managing Directors with responsibility for Finance & Group Functions.

JARDIANCE® and OFEV® drive sales growth in Human Pharma

The Human Pharma business achieved currency-adjusted net sales growth of 13.6 percent to 18.5 billion EUR, driven by JARDIANCE® and OFEV®.

JARDIANCE®, which is used to treat type 2 diabetes and heart failure with reduced and preserved ejection fraction, was the company’s most significant growth and revenue contributor, with net sales of 5.8 billion EUR and a currency-adjusted growth of 39.1 percent in 2022.

OFEV® was the company’s second-strongest revenue contributor. OFEV® is a medicine for the treatment of patients with idiopathic pulmonary fibrosis as well as certain fibrosing interstitial lung diseases. OFEV® generated net sales of 3.2 billion EUR, representing a currency-adjusted growth of 20.6 percent in 2022.

The biopharmaceuticals contract manufacturing business achieved annual net sales of over 1 billion EUR, reinforcing the company’s position as a leading manufacturer of biopharmaceuticals worldwide.

Animal Health to launch around 20 new products, starting in 2023

Animal Health experienced the effects of the economic slowdown in North America, intense competition and declining net sales of swine vaccines in China. Net Sales were on a comparable level with 2021 at 4.6 billion EUR in 2022. NEXGARD®, a medication for flea and tick protection for dogs, rose by currency-adjusted 8.0 percent to reach more than 1 billion EUR in annual sales, marking an industry-first.

R&D investments in Animal Health amounted to 464 million EUR in 2022, or 10 percent of the business unit’s sales, well exceeding industry average. Animal Health has an ambitious schedule to launch about 20 new products, starting this year, including novel flea and tick products for cats and dogs and a breakthrough oral product for diabetes in cats.

Looking ahead, Boehringer Ingelheim anticipates moderate growth in 2023, on a comparable basis, with a slight increase in its operating income, creating the fundamentals for bringing more innovative medicines to patients and animals.

Click here for the full release: Boehringer Ingelheim reaches more patients than ever, innovation drives growth | Boehringer Ingelheim (boehringer-ingelheim.com)

Harro Ten Wolde Head of Global Media Relations Email: [email protected] Phone Number: +49 (6132) 77-181352

• share on facebook share on twitter share on google+ share on linkedin share by e-mail watch our channel
• Award Applications
• Exhibitions

• Award Benefits
• Award Archive

Good Design Awards Tell a friend

Designers: Julia Schmidt, 3st kommunikation, Mainz, Germany Manufacturer: Boehringer Ingelheim GmbH, Ingelheim am Rhein, Germany

Boehringer Ingelheim is one of the world’s leading research-driven pharmaceutical companies. The Boehringer Ingelheim Annual Report is aimed at stakeholders around the world. The 2022 Annual Report consistently continues the development started in the previous year and is the first Boehringer Ingelheim corporate report to be published as an online-only publication.

Responsibility for future generations is part of the self-image of this long-established family-owned company and is firmly anchored in Boehringer Ingelheim's Purpose: Transforming lives for generations. The Corporate Report 2022 is titled "Generations" and illustrates Boehringer Ingelheim's claim with exciting stories in narrative diversity and in surprising formats. Interactive graphics, micro animations, videos, and other scrolly-telling elements with a responsive design that combines profound information in a modern journalistic format with an entertaining user experience.

• Privacy Statement
• Applications

First half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline

Author of the article:

You can save this article by registering for free here . Or sign-in if you have an account.

Article content

• Growing late-stage research pipeline, addressing areas of high unmet medical need
• Pipeline includes areas such as rare skin disease, pulmonary fibrosis, oncology and central nervous system disease
• Net sales rise currency-adjusted by 9.5 percent to 11.2 billion EUR

INGELHEIM, Germany — Boehringer Ingelheim, a leading research-driven biopharmaceutical company, continued to increase its supply of medicine to patients in the first half of 2022, as it expanded its research pipeline in an increasingly challenging economic, political and regulatory environment.

First half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline Back to video

Subscribe now to read the latest news in your city and across Canada.

• Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, Victoria Wells and others.
• Daily content from Financial Times, the world's leading global business publication.
• Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
• National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
• Daily puzzles, including the New York Times Crossword.

Create an account or sign in to continue with your reading experience.

• Access articles from across Canada with one account.
• Share your thoughts and join the conversation in the comments.
• Enjoy additional articles per month.
• Get email updates from your favourite authors.

Sign In or Create an Account

Boehringer Ingelheim has experienced strong momentum through greater investment in Research & Development (R&D), accelerated development of its pipeline and business development opportunities. The company also closed 11 R&D partnership and license deals so far this year, with a focus on new modalities such as protein degraders, antimicrobial resistance, regenerative medicine, oncology and data science.

Fueled by ongoing strong demand for the company’s human heart failure, diabetes and respiratory treatments, and its products for pets, currency-adjusted net sales rose by 9.5 percent to 11.2 billion EUR.

“Despite a volatile economic environment, we were able to supply more patients with the treatments that make a difference to them, while advancing our pipeline in Human Pharma as well as in Animal Health striving to transform lives where medical need is high,” said Hubertus von Baumbach, Chairman of the Board of Managing Directors.

Boehringer Ingelheim has earmarked 25 billion EUR for investments in R&D and an additional 7 billion EUR for new production technologies over the next five years. The company anticipates running eight active human medicines registrational trials by the end of the year, with the potential of bringing 15 new products to patients by 2027.

“Although we expect economic uncertainties to persist in the second half of the year, we remain confident that we can achieve our goals for 2022 and proceed on our innovation-driven path,” said Michael Schmelmer, Member of the Board of Managing Directors, responsible for Finance & Group Functions. “We will continue to focus on and invest in our most promising assets to bring the best value to patients.”

Net sales in Human Pharma were up 11.8 percent (currency-adjusted) during the first six months of 2022 at 8.4 billion EUR, mainly driven by diabetes treatment of the JARDIANCE ® family at 2.5 billion EUR and the respiratory medicine OFEV ® at 1.5 billion EUR.

Growth in the Animal Health business amounted to 1.2 percent (currency-adjusted) to 2.4 billion EUR. The business was impacted by challenging market conditions including inflation, COVID-19 lockdowns, outbreaks of African Swine Fever and supply chain constraints. Net sales of NEXGARD ® , a parasiticide for dogs, increased 13.7 percent (currency-adjusted) to 593 million EUR, while HEARTGARD ® , which prevents heartworm disease in dogs, rose 4.4 percent to 197 million EUR.

For the remainder of the year Boehringer Ingelheim is anticipating regulatory updates for Spesolimab, a potential treatment for flares in generalized pustular psoriasis (GPP), a rare, life-threatening neutrophilic skin disease. The company will also present promising data on JARDIANCE ® for the treatment of patients with chronic kidney disease. In addition, major product launches are expected for Animal Health in 2022 and 2023.

Click here for the full release: https://www.boehringer-ingelheim.com/about-us/corporate-profile/boehringer-ingelheim-2022-half-year-results

View source version on businesswire.com: https://www.businesswire.com/news/home/20220803005402/en/

Harro Ten Wolde Head of Global Media Relations Email: [email protected] Phone Number: +49 (6132) 77-181352

Postmedia is committed to maintaining a lively but civil forum for discussion. Please keep comments relevant and respectful. Comments may take up to an hour to appear on the site. You will receive an email if there is a reply to your comment, an update to a thread you follow or if a user you follow comments. Visit our Community Guidelines for more information.

Young Canadians think retiring at 65 is an outdated concept

Posthaste: canada’s middle class is losing momentum as wealth gap widens, taxes should not wag the tail of the investment dog, but that's what trudeau wants, opinion: the hidden federal budget assumption that most commentary missed, here's what you need to know about the increased capital gains tax.

This website uses cookies to personalize your content (including ads), and allows us to analyze our traffic. Read more about cookies here . By continuing to use our site, you agree to our Terms of Service and Privacy Policy .

You've reached the 20 article limit.

You can manage saved articles in your account.

and save up to 100 articles!

Looks like you've reached your saved article limit!

You can manage your saved articles in your account and clicking the X located at the bottom right of the article.

• Taking cancer care personally can make a world of difference
• Treating the whole patient to improve liver function
• Schizophrenia: beyond the stigma
• Transforming retinal health for individuals with diabetes
• Happy cats, happy owners
• Animal vaccines are a lynchpin of global food security
• Hearing the future
• Artificial Intelligence serving patients
• Tackling health disparities through drone delivery
• Every drop counts
• Upskilling to keep ahead
• Orchestrating a global pharmaceutical supply chain
• Life forward
• The Board of Managing Directors
• The Shareholders’ Perspective

Highlights 2023

PDF / 4,6 MB

The Shareholders’ Perspective 2023

PDF / 0,4 MB

Key Aspects 2023

PDF / 1,4 MB

Product Portfolio

Archive Annual Reports

Annual Report 2022

Annual Report 2021

PDF / 8,4 MB

Annual Report 2020

PDF / 9,4 MB

Annual Report 2019

PDF / 14,8 MB

Annual Report 2018

PDF / 5,9 MB

About Cookies

In order to analyse the use and to improve our websites and to inform you about our company on other websites, we would like to use cookies. If you agree, please click “Accept all”. If you would like to receive more detailed information, go to Data privacy ↗

• Go to illumina.com

Press Release

Illumina and boehringer ingelheim announce companion diagnostic partnership.

SAN DIEGO, Jan. 10, 2022 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) today announced a partnership with Boehringer Ingelheim to develop companion diagnostics (CDx) for several programs in Boehringer Ingelheim's oncology pipeline. The partnership aims to accelerate the development of therapy selection and precision medicines for patients with advanced cancer.

The partnership spans current and future CDx programs, with plans to add CDx claims to an in vitro diagnostic test Illumina is developing that is based on the content of TruSight™ Oncology 500 (TSO 500). The first program will co-develop a CDx for a Boehringer Ingelheim investigational medicine.

"We are delighted that Boehringer Ingelheim has chosen Illumina to be its long-term partner in the development of companion diagnostics for the treatment of cancers," said Joydeep Goswami, Chief Strategy and Corporate Development Officer of Illumina. "Illumina continues to provide the leading distributable assay enabling comprehensive genomic profiling for both tissue and liquid biopsy and together we will unlock the potential of new biomarkers to identify patients most likely to benefit from new precision medicines."

About TruSight Oncology 500 TSO 500 is a Research Use Only comprehensive pan-cancer assay designed to identify 523 known and emerging tumor biomarkers. TSO 500 utilizes both DNA and RNA from tumor samples to identify key variants critical for cancer development and progression, such as small DNA variants, fusions, and splice variants. Based on the content of TSO 500, Illumina will be adding an in vitro diagnostic test to the TruSight Oncology product family. This comprehensive tumor profiling assay will have similar chemistry and analytics to TSO 500. To learn more about TSO 500,  click here.

About Illumina Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. To learn more, visit  www.illumina.com  and connect with us on  Twitter ,  Facebook ,  LinkedIn ,  Instagram , and  YouTube .

Investors: Salli Schwartz 858.291.6421 [email protected]

Media: Dr. Karen Birmingham EMEA: +44 7500 105665 US: 646.355.2111 [email protected]

SOURCE Illumina, Inc.

• Email Alerts

To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.

At Illumina, Inc., we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.

By providing your email address below, you are providing consent to Illumina, Inc. to send you the requested Investor Email Alert updates.

Email Alert Sign Up Confirmation

General Inquiries

Salli Schwartz, Vice President lllumina Investor Relations 5200 Illumina Way San Diego, CA 92122

858.291.6421 [email protected]

Transfer Agent

Computershare Trust Company, N.A. Courier Delivery: P.O. Box 43006 Providence RI 02940-3006 Overnight Delivery: 150 Royall St. STE 101 Canton, MA 02021

877.373.6374 www.computershare.com

Tools & Links

• Latest Presentation
• SEC Filings
• Q1’21 Earnings Results

Innovative technologies

At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics.

For Research Use Only. Not for use in diagnostic procedures (except as specifically noted).

© Illumina, Inc. All rights reserved.

All trademarks are the property of Illumina, Inc. or their respective owners. For specific trademark information, see www.illumina.com/company/legal.html .

Sanofi to pay $100 million to settle Zantac cancer lawsuits

Sanofi will pay more than $100 million to settle about 4,000 lawsuits accusing the French drugmaker of failing to warn users that its Zantac heartburn medicine could cause cancer, according to people familiar with the deal.

The settlement was announced earlier this month, but the amount was not made public at that time. The deal provides former Zantac users with an average of more than $25,000 per claim, said the people, who requested anonymity because they weren’t authorized to speak publicly.

But the relatively modest settlement should please Sanofi investors, who’ve worried in the past about the financial fallout of thousands of US lawsuits targeting Zantac makers such as Sanofi and GSK Plc, which originally developed the product.

Both companies’ shares rose to session highs after the news, with Sanofi up as much as 2% in Paris and GSK rising as much as 3% in London trading.

The settlement mainly applies to state court cases outside Delaware, where a judge is considering whether to allow the scientific evidence underlying more than 70,000 suits. A federal judge in Florida threw out more than 5,000 suits in 2022, saying the science behind the cancer claims was flawed.

Sanofi declined to comment on “speculation and rumors” about the settlement amount and denied that Zantac causes cancer. “Sanofi is settling these cases, not because we believe the claims have any merit, but rather to avoid the expense and ongoing distraction of the litigation,” a Sanofi spokesperson said.

The total payout on the accord will be affected by how many of the 4,000 plaintiffs choose to accept the settlement offer or continue litigating, the people said. Other cases could be removed from the settlement for procedural reasons, they added.

Concerns about exposure to the Zantac cases helped wipe out about $45 billion in market value from GSK and Sanofi’s stock in the summer of 2022. The shares have since recovered. Analysts say the companies still face billions in potential damages, however.

GSK has settled a number of Zantac suits in California for terms that weren’t disclosed. One case against the UK drugmaker is likely to make it to a jury is set to start April 30 in state court in Chicago. Angela Valadez, 89, contends she used the heartburn treatment for nearly 20 years before being diagnosed with cancer. GSK and Boehringer Ingelheim GmbH, another company that made and sold Zantac, are the defendants in the case.

Zantac hit the US market as a prescription drug in 1983 before becoming an over-the-counter heartburn treatment in 1996. It was owned by several companies, including Pfizer Inc. and Boehringer before Sanofi acquired it in 2017. Former users allege the companies knew Zantac posed a cancer risk and sold it anyway without warnings. Makers of a generic version of the drug also are being sued.

Zantac was recalled in 2019, about a month after an independent lab announced publicly it found the likely carcinogen NDMA in the drug. The lab’s research indicated Zantac’s active ingredient at the time – ranitidine – formed NDMA over time or in elevated temperatures. US regulators confirmed the findings in April 2020 and ordered the medicine off the market.

Sanofi has since won approval to return Zantac to US store shelves, but without ranitidine. It’s now made with famotidine, the active ingredient in competitor Pepcid. Zantac is still one of the US’s leading heartburn treatments in a market that generated $14 billion in sales last year.

Can total joint replacement restore your quality of life?

If you suffer from joint pain, you know how it can greatly affect the quality of your life.